Phuturdex › Diseases › Melanoma
Drugs in development · updated 30 October 2026
Melanoma: drugs in development
As of 30 October 2026 there are 401 active clinical trials (recruiting or ongoing, phases I–III) on 352 drugs for melanoma. 219 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 219 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| PembrolizumabKEYTRUDA, MK-3475 | II–III | 106 | NCT06624644 |
| NivolumabOpdivo, ONO-4538 | II–III | 91 | NCT02339571 |
| IpilimumabYERVOY, ipililumab IV | II–III | 52 | NCT02339571 |
| BinimetinibMEK162, Mektovi® | III | 18 | NCT04657991 |
| Relatlimab | II–III | 16 | NCT06624644 |
| EncorafenibBraftovi® | III | 14 | NCT04657991 |
| AtezolizumabTecentriq, MPDL3280A | II–III | 12 | NCT05770102 |
| CemiplimabREGN2810, Libtayo® | III | 12 | NCT06246916 |
| TrametinibMekinist®, Spexotras® | III | 12 | NCT06346067 |
| DabrafenibTafinlar®, Finlee® | III | 11 | NCT02224781 |
| PaclitaxelTaxol, Paxlitaxel | III | 11 | NCT06008106 |
| TemozolomideTemodal, Temodar | II–III | 10 | NCT06624644 |
| CisplatinCis Platinum, Cisplatine | III | 8 | NCT06008106 |
| CarboplatinCarboplatine, Paraplatin | III | 7 | NCT06008106 |
| LifileucelLN-145, Amtagvi® | III | 6 | NCT05727904 |
Sorted by most advanced phase and number of active trials. Showing 15 of 133 drugs.
All 352 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Uveal melanoma 49 drugs
- Metastasis 493 drugs
- Non-small-cell lung carcinoma 726 drugs
- Renal cell carcinoma 228 drugs
- Cutaneous malignant melanoma 13 drugs
- Stomach neoplasm 340 drugs
- Hepatocellular carcinoma 266 drugs
- Colorectal neoplasm 534 drugs
- Adenocarcinoma 111 drugs
- Ovarian neoplasm 411 drugs
- Sarcoma 204 drugs
- Neoplasm 671 drugs
Broader categories
- Skin disease 34 drugs
- Skin and connective tissue diseases 3 drugs
- Neuroectodermal tumor 3 drugs
- Nerve tissue neoplasm 4 drugs
- Neuroendocrine tumor 84 drugs
- Germ cell and embryonal neoplasms 35 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D008545 “Melanoma”.